ReDS-Guided Decongestion in Acute Heart Failure (ReDS-LATAM HF) (ReDS-LATAM HF)
ReDS-LATAM HF: A Randomized Trial of Remote Dielectric Sensing-Guided Decongestion in Acute Heart Failure
Heart failure (HF) is a leading cause of hospitalization, with high rates of early readmission largely driven by residual congestion at discharge. Conventional methods to assess congestion are often imprecise and may fail to guide optimal decongestive therapy.
Remote Dielectric Sensing (ReDS) is a non-invasive technology that provides a rapid and objective estimate of lung fluid content. This study aims to evaluate whether a ReDS-guided decongestion strategy improves clinical outcomes compared with standard care in patients hospitalized for acute heart failure.
In this randomized controlled trial, patients will be assigned 1:1 to a ReDS-guided strategy or standard care. ReDS measurements will be performed in both groups but will only guide treatment in the intervention arm.
The primary endpoint is a composite of all-cause mortality, heart failure rehospitalization, or unplanned HF visit within 30 (±5) days after discharge.
연구 개요
상세 설명
Congestion is the main driver of hospitalization and adverse outcomes in acute heart failure (AHF). Residual congestion at discharge is common and associated with increased risk of early rehospitalization and mortality. However, current approaches to assess congestion rely on clinical judgment and indirect markers, which may be insufficient to guide therapy.
Remote Dielectric Sensing (ReDS) is a non-invasive technology that quantifies lung fluid content within seconds. It provides an objective measurement that has been validated against imaging and invasive hemodynamic parameters.
The ReDS-LATAM HF study is a pragmatic, single-center, randomized controlled trial designed to assess whether a ReDS-guided strategy improves early outcomes in patients hospitalized with AHF.
Patients will be randomized 1:1 to either a ReDS-guided strategy, in which daily measurements are used to adjust diuretic therapy according to a predefined protocol, or to standard care based on usual clinical practice. ReDS measurements will be obtained in both groups, but values will be blinded in the control arm.
The primary outcome is a composite of all-cause mortality, heart failure rehospitalization, or unplanned HF visit within 30 (±5) days after discharge. Secondary analyses will include individual components of the primary endpoint, changes in biomarkers, and safety outcomes.
This study also aims to evaluate the feasibility of implementing this technology in a real-world Latin American setting.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, 아르헨티나, 1428
- Instituto Cardiovascular de Buenos Aires
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥21 years
- Hospitalization for acute heart failure with signs of congestion within 48 hours of admission
- Elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP equivalent)
- Ability to provide informed consent
Exclusion Criteria:
- Need for inotropes, vasopressors, or mechanical circulatory support at enrollment Heart transplant recipient Mechanical ventilation at enrollment Conditions that prevent reliable ReDS measurement Planned cardiac surgery or intervention during the study period Severe renal dysfunction (eGFR <15 mL/min/1.73 m² or dialysis) Life expectancy <3 months Inability to complete follow-up Participation in another interventional trial Any condition that may compromise safety or study integrity
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ReDS-Guided Decongestion Strategy
Participants assigned to this arm will undergo daily Remote Dielectric Sensing (ReDS) measurements during hospitalization.
ReDS values will be available to the treating physician and used to guide adjustment of diuretic therapy according to a predefined protocol aimed at achieving effective decongestion while avoiding volume depletion.
Treatment decisions, including diuretic dosing and escalation, will be based on ReDS thresholds in combination with clinical judgment.
Patients will be discharged based on clinical stability criteria, incorporating ReDS values as part of the decongestion assessment.
|
Remote Dielectric Sensing (ReDS) is a non-invasive device that estimates lung fluid content by measuring the dielectric properties of thoracic tissues.
The system consists of wearable sensors positioned on the anterior and posterior chest, providing a quantitative measurement within approximately 45 seconds.
In this study, ReDS measurements will be performed daily during hospitalization.
In the intervention arm, results will be available to the treating physician and used to guide diuretic therapy according to predefined thresholds.
In the control arm, measurements will be performed but results will remain blinded and will not influence clinical decision-making.
Standard care consists of treatment based on routine clinical assessment, including physical examination, laboratory parameters, and institutional protocols.
Diuretic therapy and other treatments will be adjusted according to the treating physician's clinical judgment, without access to ReDS measurements.
|
|
활성 비교기: Standar of care
Participants assigned to this arm will receive standard care based on routine clinical assessment, including physical examination, laboratory parameters, and usual institutional practice.
Remote Dielectric Sensing (ReDS) measurements will be performed daily during hospitalization; however, the results will be blinded and not available to the treating physician.
Treatment decisions, including diuretic therapy, will be made according to clinical judgment without access to ReDS data.
|
Standard care consists of treatment based on routine clinical assessment, including physical examination, laboratory parameters, and institutional protocols.
Diuretic therapy and other treatments will be adjusted according to the treating physician's clinical judgment, without access to ReDS measurements.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite of all-cause mortality, heart failure rehospitalization, or unplanned heart failure visit
기간: Within 30 (±5) days after hospital discharge
|
Time to first occurrence of a composite endpoint including all-cause mortality, rehospitalization for heart failure (defined as an unplanned hospital admission >24 hours requiring intensification of heart failure therapy), or an unplanned visit for heart failure (emergency department or urgent outpatient visit requiring treatment escalation) within 30 (±5) days after discharge.
|
Within 30 (±5) days after hospital discharge
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- ReDS-LATAM HF
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .